These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial.
    Author: Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA.
    Journal: Cancer Res; 1986 Apr; 46(4 Pt 2):2101-4. PubMed ID: 3512079.
    Abstract:
    In a Phase I study, recombinant interleukin-2 (IL-2) or autochthohous lymphokine-activated killer (LAK) cells were used to treat nine patients with malignant glioma. One patient received the combination of IL-2 and LAK cells. LAK cells were generated by culturing IL-2 with peripheral blood lymphocytes obtained from brain tumor patients. Escalating doses of LAK cells (10(8)-10(10) or recombinant IL-2 (10(4)-10(6) units) were administered by direct injection into the brain tissue surrounding the cavity left following operative tumor removal. There have been no signs of systemic or neurotoxicity following treatment. The tumor selective killing of the LAK cells used for these treatments was demonstrated by their ability to lyse glioma cells but not normal cells in vitro using a chromium release microcytotoxicity assay.
    [Abstract] [Full Text] [Related] [New Search]